388 related articles for article (PubMed ID: 12823077)
1. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.
Westenberg HG; Stein DJ; Yang H; Li D; Barbato LM
J Clin Psychopharmacol; 2004 Feb; 24(1):49-55. PubMed ID: 14709947
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
4. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
5. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
Goodman WK; Kozak MJ; Liebowitz M; White KL
Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
[TBL] [Abstract][Full Text] [Related]
6. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
9. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
Riddle MA; Reeve EA; Yaryura-Tobias JA; Yang HM; Claghorn JL; Gaffney G; Greist JH; Holland D; McConville BJ; Pigott T; Walkup JT
J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):222-9. PubMed ID: 11211371
[TBL] [Abstract][Full Text] [Related]
10. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
[TBL] [Abstract][Full Text] [Related]
12. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
[TBL] [Abstract][Full Text] [Related]
13. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
16. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
[TBL] [Abstract][Full Text] [Related]
17. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder.
Black DW; Gabel J; Hansen J; Schlosser S
Ann Clin Psychiatry; 2000 Dec; 12(4):205-11. PubMed ID: 11140921
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
